Abstract 778: The identification and structure-guided optimisation of potent and selective inhibitors of oncogenes in medullary thyroid carcinoma and lung adenocarcinoma
Roger J. Butlin(University of Manchester), Donald Ogilvie(Bioscience Research), Daniel P. Mould(University of Manchester), Rebecca Newton(University of Manchester), Nikki March(University of Manchester), Kate Bowler(University of Manchester), Gemma V. Hopkins(University of Manchester), Mandy Watson(University of Manchester), Sarah V. Holt(Pharma Nord (United Kingdom)), Samantha Fritzl(University of Manchester), Alexandra Stowell(University of Manchester), Allan M. Jordan(Signature Research (United States)), Ian D. Waddell(Charles River Laboratories (United Kingdom)), Ben Acton(Cancer Research UK Manchester Institute), Kristin Goldberg(University of Manchester), Stuart Jones(University of Manchester), Niall M. Hamilton(Ninewells Hospital), Bohdan Waszkowycz(University of Manchester), Helen Small(University of Manchester)
Cited by 0
Related Papers
AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer
|Cancer Research|2005|710
Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression
|Journal of Cell Science|2004|344
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia
|Nature Cancer|2021|279
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
|British Journal of Cancer|2012|111
Silencing Cenp-F weakens centromeric cohesion, prevents chromosome alignment and activates the spindle checkpoint
|Journal of Cell Science|2005|108